Endothelin-1 (1-31): From chymase-dependent synthesis to cardiovascular pathologies

Vascular Pharmacology

Volumn 49, Issue 2-3, 2008, Pages 51-62

  D'Orleans Juste P ^a   Houde, M ^a   Rae, G A ^b   Bkaily, G ^a   Carrier, E ^a   Simard, E ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Big endothelin 1; Chymase; Endothelin 1 (1 31); Endothelin converting enzyme; Neutral endopeptidase 24 11

Indexed keywords

2 [2 [2 [5 AMINO 2 (3 METHOXYPHENYL) 6 OXO 1,6 DIHYDROPYRIMIDIN 1 YL]ACETAMIDO] 3 PHENYLPROPIONYL]BENZOXAZOLE 5 CARBOXYLIC ACID METHYL ESTER; 2 [4 (5 FLUORO 3 METHYLBENZO[B]THIOPHEN 2 YL)SULFONAMIDE 3 METHANESULFONYLPHENYL]OXAZOLE 4 CARBOXYLIC ACID; 3 (3 AMINOPHENYLSULFONYL) 7 CHLOROQUINAZOLINE 2,4(1H,3H) DIONE; 3 [(3 AMINO 4 CARBOXY)PHENYLSULFONYL] 7 CHLOROQUINAZOLINE 2,4(1H,3H) DIONE; 3 [(3,4 DIMETHOXYPHENYL)SULFONYL] 1 (3,4 DIMETHYLPHENYL)IMIDAZOLINE 2,4 DIONE; 4 [1 (NAPHTHYLMETHYL)BENZIMIDAZOL 2 YLTHIO]BUTANOIC ACID; 4 [1 [[BIS(4 METHYLPHENYL)METHYL]CARBAMOYL] 3 (2 ETHOXYBENZYL) 4 OXO 2 AZETIDINYLOXY]BENZOIC ACID; 4 [5 AMINO 2 (3 CHLOROPHENYL) 6 OXO 1,6 DIHYDROPYRIMIDIN 1 YLACETAMIDO] N BENZYL 2,2 DIFLUORO 3 OXO 5 PHENYLPENTANAMIDE; ANGIOTENSIN I; ANGIOTENSIN II; BENZO[B]THIOPHENE 2 SULFONAMIDE; BETA KETOPHOSPHONATE 1; BIG ENDOTHELIN 1; BOSENTAN; C 41; CGS 35066; CHYMASE; CHYMASE INHIBITOR; CHYMOSTATIN; CROMOGLYCATE DISODIUM; ENDOTHELIN 1; ENDOTHELIN 1 DERIVATIVE; ENDOTHELIN 1 [1-31]; JNJ 10311795; KETOTIFEN; LODOXAMIDE; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; RO 677447; RWJ 355871; SERINE PROTEINASE; SF 2809; SM 19712; SUN C8007; SUN C8257; SURAMIN; TEI E548; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANILAST; TY 51076; TY 51184; TY 51469; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 40018; Y 40079;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INTERSTITIUM; MAST CELL; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNTHESIS; VASOCONSTRICTION;

EID: 50949114137     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.06.007     Document Type: Review

References (184)

1. Abassi Z.A., Tate J.E., Golomb E., and Keiser H.R. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 20 (1992) 89-95
2. Abonia J.P., Friend D.S., Austen Jr. W.G., Moore Jr. F.D., Carroll M.C., Chan R., Afnan J., Humbles A., Gerard C., Knight P., Kanaoka Y., Yasuda S., Morokawa N., Austen K.F., Stevens R.L., and Gurish M.F. Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J. Immunol. 174 (2005) 7285-7291
3. Akahoshi F., Ashimori A., Sakashita H., Yoshimura T., Imada T., Nakajima M., Mitsutomi N., Kuwahara S., Ohtsuka T., Fukaya C., Miyazaki M., and Nakamura N. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic alpha-keto heterocycles as novel inhibitors of human chymase. J. Med. Chem. 44 (2001) 1286-1296
4. Akahoshi F., Ashimori A., Sakashita H., Yoshimura T., Eda M., Imada T., Nakajima M., Mitsutomi N., Kuwahara S., Ohtsuka T., Fukaya C., Miyazaki M., and Nakamura N. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase. J. Med. Chem. 44 (2001) 1297-1304
5. Andersson M.K., Karlson U., and Hellman L. The extended cleavage specificity of the rodent beta-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. Mol. Immunol. 45 (2008) 766-775
6. Arakawa K., and Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 36 (2000) 638-641
7. Arinami T., Ishikawa M., Inoue A., Yanagisawa M., Masaki T., Yoshida M.C., and Hamaguchi H. Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am. J. Hum. Genet. 48 (1991) 990-996
8. Arnal J.F., Castano C., Maupas E., Mugniot A., Darblade B., Gourdy P., Michel J.B., and Bayard F. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis 155 (2001) 291-295
9. Askenase P.W., Van Loveren H., Kraeuter-Kops S., Ron Y., Meade R., Theoharides T.C., Nordlund J.J., Scovern H., Gerhson M.D., and Ptak W. Defective elicitation of delayed-type hypersensitivity in W/Wv and SI/SId mast cell-deficient mice. J. Immunol. 131 (1983) 2687-2694
10. Azuma H., Banno K., and Yoshimura T. Pharmacological properties of N-(3¢,4¢-dimethoxycinnamoyl) anthranilic acid (N-5¢), a new anti-atopic agent. Br. J. Pharmacol. 58 (1976) 483-488
11. Babaei S., Picard P., Ravandi A., Monge J.C., Lee T.C., Cernacek P., and Stewart D.J. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc. Res. 48 (2000) 158-167
12. Balcells E., Meng Q.C., Johnson Jr. W.H., Oparil S., and Dell'Italia L.J. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol. 273 (1997) H1769-H1774
13. Banes-Berceli A.K., Ketsawatsomkron P., Ogbi S., Patel B., Pollock D.M., and Marrero M.B. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1291-H1299
14. Baraniuk J.N., Ohkubo K., Kwon O.J., Mak J., Ali M., Davies R., Twort C., Kaliner M., Letarte M., and Barnes P.J. Localization of neutral endopeptidase (NEP) mRNA in human bronchi. Eur. Respir. J. 8 (1995) 1458-1464
15. Battistini B., Berthiaume N., Kelland N.F., Webb D.J., and Kohan D.E. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp. Biol. Med. (Maywood). 231 (2006) 653-695
16. Beara-Lasic L., Knotek M., Cejvan K., Jaksic O., Lasic Z., Skoric B., Brkljacic V., and Banfic H. The effect of big endothelin-1 in the proximal tubule of the rat kidney. Br. J. Pharmacol. 120 (1997) 625-630
17. Bohm F., Ahlborg G., and Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin. Sci. (Lond.). 102 (2002) 321-327
18. Bohm F., Johansson B.L., Hedin U., Alving K., and Pernow J. Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis 160 (2002) 215-222
19. Bot I., de Jager S.C., Zernecke A., Lindstedt K.A., van Berkel T.J., Weber C., and Biessen E.A. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 115 (2007) 2516-2525
20. Brands M., Erguden J.K., Hashimoto K., Heimbach D., Schroder C., Siegel S., Stasch J.P., and Weigand S. Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis. Bioorg. Med. Chem. Lett. 15 (2005) 4201-4205
21. Brands M., Erguden J.K., Hashimoto K., Heimbach D., Krahn T., Schroder C., Siegel S., Stasch J.P., Tsujishita H., Weigand S., and Yoshida N.H. Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation. Chem. Med. Chem. 1 (2006) 96-105
22. Church M.K., and Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmacol. 90 (1987) 421-429
23. Clarke C.W., and May C.S. A comparison of the efficacy of ketotifen (HC 20-511) with sodium cromoglycate (SCG) in skin test positive asthma. Br. J. Clin. Pharmacol. 10 (1980) 473-476
24. Cui P., Tani K., Kitamura H., Okumura Y., Yano M., Inui D., Tamaki T., Sone S., and Kido H. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J. Leukoc. Biol. 70 (2001) 306-312
25. Daugherty A., Rateri D.L., Lu H., Inagami T., and Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110 (2004) 3849-3857
26. De Campo B.A., Goldie R.G., Jeng A.Y., and Henry P.J. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice. Clin. Sci. (Lond.) 103 Suppl 48 (2002) 353S-356S
27. de Garavilla L., Greco M.N., Sukumar N., Chen Z.W., Pineda A.O., Mathews F.S., Di Cera E., Giardino E.C., Wells G.I., Haertlein B.J., Kauffman J.A., Corcoran T.W., Derian C.K., Eckardt A.J., Damiano B.P., Andrade-Gordon P., and Maryanoff B.E. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J. Biol. Chem. 280 (2005) 18001-18007
28. De Lombaert S., Ghai R.D., Jeng A.Y., Trapani A.J., and Webb R.L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem. Biophys. Res. Commun. 204 (1994) 407-412
29. Dhaun N., Pollock D.M., Goddard J., and Webb D.J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci. 28 (2007) 573-579
30. Doggrell S.A., and Wanstall J.C. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can. J. Physiol. Pharmacol. 83 (2005) 123-130
31. D'Orleans-Juste P., Lidbury P.S., Warner T.D., and Vane J.R. Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochem. Pharmacol. 39 (1990) R21-R22
32. D'Orleans-Juste P., Telemaque S., Claing A., Ihara M., and Yano M. Human big-endothelin-1 and endothelin-1 release prostacyclin via the activation of ET1 receptors in the rat perfused lung. Br. J. Pharmacol. 105 (1992) 773-775
33. D'Orleans-Juste P., Gratton J.-P., Bkaily G., and Giaid A. Activity and distribution of endothelin-converting enzyme in the lung. In: Goldie R.G., and Hay D.W.P. (Eds). Pulmonary Actions of the Endothelins, Chapter 4 (1999) 53-73
34. D'Orleans-Juste P., Labonte J., Bkaily G., Choufani S., Plante M., and Honore J.C. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. 95 (2002) 221-238
35. Eady R.P., Greenwood B., Jackson D.M., Orr T.S., and Wells E. The effect of nedocromil sodium and sodium cromoglycate on antigen-induced bronchoconstriction in the Ascaris-sensitive monkey. Br. J. Pharmacol. 85 (1985) 323-325
36. Ebbe S., Phalen E., and Stohlman Jr. F. Abnormalities of megakaryocytes in S1-S1d mice. Blood 42 (1973) 865-871
37. Emoto N., and Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270 (1995) 15262-15268
38. Fecteau M.H., Honore J.C., Plante M., Labonte J., Rae G.A., and D'Orleans-Juste P. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 46 (2005) 87-92
39. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85 (1999) 906-911
40. Fleming I. Signaling by the angiotensin-converting enzyme. Circ. Res. 98 (2006) 887-896
41. Forsberg E., Pejler G., Ringvall M., Lunderius C., Tomasini-Johansson B., Kusche-Gullberg M., Eriksson I., Ledin J., Hellman L., and Kjellen L. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400 (1999) 773-776
42. Fukami H., Imajo S., Ito A., Kakutani S., Shibata H., Sumida M., Tanaka T., Niwata S., Saitoh M., Kiso Y., Miyazaki M., Okunishi H., Urata H., and Arakawa K. Substituted 3-phenylsulfonylquinazoline-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. Drug Des. Discov. 17 (2000) 69-84
43. Galli S.J., Iemura A., Garlick D.S., Gamba-Vitalo C., Zsebo K.M., and Andrews R.G. Reversible expansion of primate mast cell populations in vivo by stem cell factor. J. Clin. Invest. 91 (1993) 148-152
44. Giaid A., Gibson S.J., Ibrahim B.N., Legon S., Bloom S.R., Yanagisawa M., Masaki T., Varndell I.M., and Polak J.M. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc. Natl. Acad. Sci. U S A. 86 (1989) 7634-7638
45. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., and Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328 (1993) 1732-1739
46. Goldie R.G., D'Aprile A.C., Self G.J., Rigby P.J., and Henry P.J. Influence of endothelin-1(1-31) on smooth muscle tone and cholinergic nerve-mediated contraction in rat isolated trachea. J. Cardiovasc. Pharmacol. 36 (2000) S228-S231
47. Gonon A.T., Bulhak A., Broijersen A., and Pernow J. Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart. Br. J. Pharmacol. 144 (2005) 860-866
48. Gratton J.P., Rae G.A., Claing A., Telemaque S., and D'Orleans-Juste P. Different pressor and bronchoconstrictor properties of human big-endothelin-1, 2 (1-38) and 3 in ketamine/xylazine-anaesthetized guinea-pigs. Br. J. Pharmacol. 114 (1995) 720-726
49. Gratton J.P., Maurice M.C., Rae G.A., and D'Orleans-Juste P. Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Am. J. Hypertens. 8 (1995) 1121-1127
50. Guenet J.L., Marchal G., Milon G., Tambourin P., and Wendling F. Fertile dominant spotting in the house mouse. J. Hered. 70 (1979) 9-12
51. Hammoud R.A., Vaccari C.S., Nagamia S.H., and Khan B.V. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc. Health Risk Manag. 3 (2007) 937-945
52. Hara M., Ono K., Hwang M.W., Iwasaki A., Okada M., Nakatani K., Sasayama S., and Matsumori A. Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. 195 (2002) 375-381
53. Hayasaki-Kajiwara Y., Naya N., Shimamura T., Iwasaki T., and Nakajima M. Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Br. J. Pharmacol. 127 (1999) 1415-1421
54. He S., Gaca M.D., McEuen A.R., and Walls A.F. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells. J. Pharmacol. Exp. Ther. 291 (1999) 517-523
55. He S.H., and Xie H. Modulation of histamine release from human colon mast cells by protease inhibitors. World J. Gastroenterol. 10 (2004) 337-341
56. Hisaki K., Matsumura Y., Maekawa H., Fujita K., Takaoka M., and Morimoto S. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. Am. J. Physiol. 266 (1994) H422-H428
57. Hollenberg N.K. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension 35 (2000) 150-154
58. Honore J.C., Plante M., Bkaily G., Rae G.A., and D'Orleans-Juste P. Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs. Br. J. Pharmacol. 136 (2002) 819-828
59. Hoshino F., Urata H., Inoue Y., Saito Y., Yahiro E., Ideishi M., Arakawa K., and Saku K. Chymase inhibitor improves survival in hamsters with myocardial infarction. J. Cardiovasc. Pharmacol. 15 Suppl 1 (2003) S11-S18
60. Hultner L., and Ehrenreich H. Mast cells and endothelin-1: a life-saving biological liaison?. Trends Immunol. 26 (2005) 235-238
61. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., and Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U S A. 86 (1989) 2863-2867
62. Inui D., Yoshizumi M., Okishima N., Houchi H., Tsuchiya K., Kido H., and Tamaki T. Mechanism of endothelin-1-(1-31)-induced calcium signaling in human coronary artery smooth muscle cells. Am. J. Physiol. 276 (1999) E1067-E1072
63. Inui D., Yoshizumi M., Suzaki Y., Kirima K., Tsuchiya K., Houchi H., Kagami S., and Tamaki T. Effect of endothelin-1(1-31) on p38 mitogen-activated protein kinase in cultured human mesangial cells. Life Sci. 68 (2000) 635-645
64. Isaji M., Miyata H., Ajisawa Y., Takehana Y., and Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br. J. Pharmacol. 122 (1997) 1061-1066
65. Ishizawa K., Yoshizumi M., Tsuchiya K., Houchi H., Minakuchi K., Izawa Y., Kanematsu Y., Kagami S., Hirose M., and Tamaki T. Dual effects of endothelin-1 (1-31): induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. Hypertens. Res. 27 (2004) 433-440
66. Jandeleit-Dahm K., Lassila M., Davis B.J., Candido R., Johnston C.I., Allen T.J., Burrell L.M., and Cooper M.E. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J. Hypertens. 23 (2005) 2071-2082
67. Jeng A.Y., De Lombaert S., Beil M.E., Bruseo C.W., Savage P., Chou M., and Trapani A.J. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. J. Cardiovasc. Pharmacol. 36 (2000) S36-S39
68. Jeng A.Y., Mulder P., Kwan A.L., and Battistini B. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can. J. Physiol. Pharmacol. 80 (2002) 440-449
69. Jin D., Takai S., Sakaguchi M., Okamoto Y., Muramatsu M., and Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J. Pharmacol. Exp. Ther. 309 (2004) 490-497
70. Kaartinen M., Penttila A., and Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90 (1994) 1669-1678
71. Karlson U., Pejler G., Froman G., and Hellman L. Rat mast cell protease 4 is a beta-chymase with unusually stringent substrate recognition profile. J. Biol. Chem. 277 (2002) 18579-18585
72. Keidar S., Kaplan M., and Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc. Res. 73 (2007) 463-469
73. Kelland N.F., and Webb D.J. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 93 (2007) 2-4
74. Kishi F., Minami K., Okishima N., Murakami M., Mori S., Yano M., Niwa Y., Nakaya Y., and Kido H. Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem. Biophys. Res. Commun. 248 (1998) 387-390
75. Kitamura H., Cui P., Sharmin S., Yano M., and Kido H. Binding of a new bioactive 31-amino-acid endothelin-1 to an endothelin ET(B) or ET(B)-like receptor in porcine lungs. Eur. J. Pharmacol. 465 (2003) 31-38
76. Kitamura Y., Go S., and Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52 (1978) 447-452
77. Kitamura Y., Yokoyama M., Matsuda H., and Shimada M. Coincidental development of forestomach papilloma and prepyloric ulcer in nontreated mutant mice of W/Wv and SI/SId genotypes. Cancer Res. 40 (1980) 3392-3397
78. Konno T., Maruichi M., Takai S., Oku H., Sugiyama T., Uchibori T., Nagai A., Kogi K., Ikeda T., and Miyazaki M. Effect of chymase on intraocular pressure in rabbits. Eur. J. Pharmacol. 524 (2005) 132-137
79. Kovanen P.T., Kaartinen M., and Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 92 (1995) 1084-1088
80. Kovanen P.T. Mast cells: multipotent local effector cells in atherothrombosis. Immunol. Rev. 217 (2007) 105-122
81. Kunori Y., Koizumi M., Masegi T., Kasai H., Kawabata H., Yamazaki Y., and Fukamizu A. Rodent alpha-chymases are elastase-like proteases. Eur. J. Biochem. 269 (2002) 5921-5930
82. Laine P., Kaartinen M., Penttila A., Panula P., Paavonen T., and Kovanen P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99 (1999) 361-369
83. Lal S., Malhotra S., Gribben D., and Hodder D. Nedocromil sodium: a new drug for the management of bronchial asthma. Thorax 39 (1984) 809-812
84. Landry C., Santagata P., Bawab W., Fournie-Zaluski M.C., Roques B.P., Vinay P., and Crine P. Characterization of neutral endopeptidase 24.11 in dog glomeruli. Biochem. J. 291 Pt 3 (1993) 773-779
85. Laporte S., Denault J.B., D'Orleans-Juste P., and Leduc R. Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor. J. Cardiovasc. Pharmacol. 22 Suppl 8 (1993) S7-S10
86. Lavrentyev E.N., Estes A.M., and Malik K.U. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ. Res. 101 (2007) 455-464
87. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., and Burnett Jr. J.C. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325 (1991) 997-1001
88. Leslie S.J., Rahman M.Q., Denvir M.A., Newby D.E., and Webb D.J. Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide. Br J. Clin. Pharmacol. 57 (2004) 720-725
89. Li M., Liu K., Michalicek J., Angus J.A., Hunt J.E., Dell'Italia L.J., Feneley M.P., Graham R.M., and Husain A. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J. Clin. Invest. 114 (2004) 112-120
90. Libby P., and Shi G.P. Mast cells as mediators and modulators of atherogenesis. Circulation 115 (2007) 2471-2473
91. Lindenau S., von Langsdorff C., Saxena A., Paul M., and Orzechowski H.D. Genomic organisation of the mouse gene encoding endothelin-converting enzyme-1 (ECE-1) and mRNA expression of ECE-1 isoforms in murine tissues. Gene 373 (2006) 109-115
92. Lindstedt L., Lee M., and Kovanen P.T. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis 155 (2001) 87-97
93. Lu H., Rateri D.L., Feldman Jr. D.L., R.J., Fukamizu A., Ishida J., Oesterling E.G., Cassis L.A., and Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J. Clin. Invest. 118 (2008) 984-993
94. Lu Y., Wang W.Z., Liao Z., Yan X.H., Tang C.S., and Yuan W.J. Blood pressure responses of endothelin-1 1-31 within the rostral ventrolateral medulla through conversion to endothelin-1 1-21. J. Cardiovasc. Pharmacol. 46 (2005) 823-829
95. Lu Y., Wang L.G., Liao Z., Tang C.S., Wang W.Z., and Yuan W.J. Cardiovascular effects of centrally applied endothelin-1 1-31 and its relationship to endothelin-1 1-21 in rats. Auton. Neurosci. 133 (2007) 146-152
96. Lundequist A., Tchougounova E., Abrink M., and Pejler G. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J. Biol. Chem. 279 (2004) 32339-32344
97. Maguire J., and Davenport A.P. Alternative pathway to endothelin-converting enzyme for the synthesis of endothelin in human blood vessels. J. Cardiovasc. Pharmacol. 44 Suppl 1 (2004) S27-S29
98. Maguire J.J., Kuc R.E., and Davenport A.P. Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro. Br. J. Pharmacol. 134 (2001) 1360-1366
99. Maguire J.J., Wiley K.E., Kuc R.E., Stoneman V.E., Bennett M.R., and Davenport A.P. Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin. Exp. Biol. Med. (Maywood). 231 (2006) 806-812
100. Martin U., and Romer D. The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittelforschung. 28 (1978) 770-782
101. Masaki H., Mizuno Y., Tatui A., Murakami A., Koide Y., Satoh S., and Takahashi A. Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors. Bioorg. Med. Chem. Lett. 13 (2003) 4085-4088
102. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., and Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107 (2003) 2555-2558
103. Mattera G.G., Eglezos A., Renzetti A.R., and Mizrahi J. Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan. Br. J. Pharmacol. 110 (1993) 331-337
104. Maurer M., Wedemeyer J., Metz M., Piliponsky A.M., Weller K., Chatterjea D., Clouthier D.E., Yanagisawa M.M., Tsai M., and Galli S.J. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432 (2004) 512-516
105. Mawatari K., Kakui S., Harada N., Ohnishi T., Niwa Y., Okada K., Takahashi A., Izumi K., and Nakaya Y. Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis 175 (2004) 203-212
106. Mazzocchi G., Rossi G.P., Malendowicz L.K., Champion H.C., and Nussdorfer G.G. Endothelin-1[1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett. 487 (2000) 194-198
107. McDonald J.E., Padmanabhan N., Petrie M.C., Hillier C., Connell J.M., and McMurray J.J. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(d)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation 104 (2001) 1805-1808
108. McMahon E.G., Palomo M.A., Moore W.M., McDonald J.F., and Stern M.K. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc. Natl. Acad. Sci. U S A. 88 (1991) 703-707
109. Miyazaki M., Takai S., Jin D., and Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol. Ther. 112 (2006) 668-676
110. Montanari A., Biggi A., Carra N., Ziliotti M., Fasoli E., Musiari L., Perinotto P., and Novarini A. Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. Hypertension 42 (2003) 825-830
111. Muramatsu M., Katada J., Hattori M., Hayashi I., and Majima M. Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas. Eur. J. Pharmacol. 402 (2000) 181-191
112. Murray D.B., Gardner J.D., Brower G.L., and Janicki J.S. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2295-H2299
113. Murray D.B., Gardner J.D., Brower G.L., and Janicki J.S. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1251-H1257
114. Nagata N., Niwa Y., and Nakaya Y. A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 275 (2000) 595-600
115. Nakano A., Kishi F., Minami K., Wakabayashi H., Nakaya Y., and Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J. Immunol. 159 (1997) 1987-1992
116. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14 (1994) 133-140
117. Nishimoto M., Takai S., Sawada Y., Yuda A., Kondo K., Yamada M., Jin D., Sakaguchi M., Asada K., Sasaki S., and Miyazaki M. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J. Thorac. Cardiovasc. Surg. 121 (2001) 729-734
118. Nishimoto M., Takai S., Kim S., Jin D., Yuda A., Sakaguchi M., Yamada M., Sawada Y., Kondo K., Asada K., Iwao H., Sasaki S., and Miyazaki M. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 104 (2001) 1274-1279
119. Niwa Y., Nagata N., Oka M., Toyoshima T., Akiyoshi H., Wada T., and Nakaya Y. Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase. Life Sci. 67 (2000) 1103-1109
120. Niwata S., Fukami H., Sumida M., Ito A., Kakutani S., Saitoh M., Suzuki K., Imoto M., Shibata H., Imajo S., Kiso Y., Tanaka T., Nakazato H., Ishihara T., Takai S., Yamamoto D., Shiota N., Miyazaki M., Okunishi H., Kinoshita A., Urata H., and Arakawa K. Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. J. Med. Chem. 40 (1997) 2156-2163
121. Ohtsu H., Tanaka S., Terui T., Hori Y., Makabe-Kobayashi Y., Pejler G., Tchougounova E., Hellman L., Gertsenstein M., Hirasawa N., Sakurai E., Buzas E., Kovacs P., Csaba G., Kittel A., Okada M., Hara M., Mar L., Numayama-Tsuruta K., Ishigaki-Suzuki S., Ohuchi K., Ichikawa A., Falus A., Watanabe T., and Nagy A. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 502 (2001) 53-56
122. Okishima N., Yoshizumi M., Tsuchiya K., Cui P., Kitamura H., Tamaki T., and Kido H. Determination of the levels of novel 31-amino acid endothelins and endothelins in human lungs. Life Sci. 68 (2001) 2073-2080
123. Oleksyszyn J., and Powers J.C. Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases. Methods Enzymol. 244 (1994) 423-441
124. Orr T.S., and Cox J.S. Disodium cromoglycate, an inhibitor of mas cell degranulation and histamine release induced by phospholipase A. Nature 223 (1969) 197-198
125. Ozawa Y., Hasegawa T., Tsuchiya K., Yoshizumi M., and Tamaki T. Effect of endothelin-1 (1-31) on the renal resistance vessels. J. Med. Invest. 50 (2003) 87-94
126. Palaniyandi S.S., Nagai Y., Watanabe K., Ma M., Veeraveedu P.T., Prakash P., Kamal F.A., Abe Y., Yamaguchi K., Tachikawa H., Kodama M., and Aizawa Y. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp. Biol. Med. (Maywood). 232 (2007) 1213-1221
127. Palladini G., Tozzi R., and Perlini S. Cardiac mast cells in the transition to heart failure: innocent bystanders or key actors?. J. Hypertens. 21 (2003) 1823-1825
128. Pfab T., and Hocher B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J. Hypertens. 22 (2004) 883-886
129. Plante M., Honore J.C., Neugebauer W., and D'Orleans-Juste P. Endothelin-1 (1-31) induces a thiorphan-sensitive release of eicosanoids via ET(B) receptors in the guinea pig perfused lung. Clin. Sci. (Lond.) 103 Suppl 48 (2002) 128S-131S
130. Poulat P., De Champlain J., D'Orleans-Juste P., and Couture R. Receptor and mechanism that mediate endothelin- and big endothelin-1-induced phosphoinositide hydrolysis in the rat spinal cord. Eur. J. Pharmacol. 315 (1996) 327-334
131. Rebuffat P., Malendowicz L.K., Neri G., and Nussdorfer G.G. Endothelin-1[1-31] acts as a selective ETA-receptor agonist in the rat adrenal cortex. Histol. Histopathol. 16 (2001) 535-540
132. Richard V., Hurel-Merle S., Scalbert E., Ferry G., Lallemand F., Bessou J.P., and Thuillez C. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 104 (2001) 750-752
133. Rossi G.P., Andreis P.G., Colonna S., Albertin G., Aragona F., Belloni A.S., and Nussdorfer G.G. Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J. Clin. Endocrinol. Metab. 87 (2002) 322-328
134. Sakaguchi M., Takai S., Jin D., Okamoto Y., Muramatsu M., Kim S., and Miyazaki M. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur. J. Pharmacol. 493 (2004) 173-176
135. Schneider L.A., Schlenner S.M., Feyerabend T.B., Wunderlin M., and Rodewald H.R. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J. Exp. Med. 204 (2007) 2629-2639
136. Schwartz S.M., Galis Z.S., Rosenfeld M.E., and Falk E. Plaque rupture in humans and mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 705-713
137. Schweizer A., Valdenaire O., Koster A., Lang Y., Schmitt G., Lenz B., Bluethmann H., and Rohrer J. Neonatal lethality in mice deficient in XCE, a novel member of the endothelin-converting enzyme and neutral endopeptidase family. J. Biol. Chem. 274 (1999) 20450-20456
138. Sharmin S., Shiota M., Murata E., Cui P., Kitamura H., Yano M., and Kido H. A novel bioactive 31-amino acid ET-1 peptide stimulates eosinophil recruitment and increases the levels of eotaxin and IL-5. Inflamm. Res. 51 (2002) 195-200
139. Sheth P.D., Pedersen J., Walls A.F., and McEuen A.R. Inhibition of dipeptidyl peptidase I in the human mast cell line HMC-1: blocked activation of tryptase, but not of the predominant chymotryptic activity. Biochem. Pharmacol. 66 (2003) 2251-2262
140. Shimada K., Matsushita Y., Wakabayashi K., Takahashi M., Matsubara A., Iijima Y., and Tanzawa K. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem. Biophys. Res. Commun. 207 (1995) 807-812
141. Shimada K., Takahashi M., Ikeda M., and Tanzawa K. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett. 371 (1995) 140-144
142. Shiota N., Rysa J., Kovanen P.T., Ruskoaho H., Kokkonen J.O., and Lindstedt K.A. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J. Hypertens. 21 (2003) 1935-1944
143. Simko F., and Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol. Res. 48 (1999) 1-8
144. Soga Y., Takai S., Koyama T., Okamoto Y., Ikeda T., Nishimura K., Miyazaki M., and Komeda M. Attenuation of adhesion formation after
145. Suga Y., Takamori K., and Ogawa H. Skin proteasomes (high-molecular-weight protease): purification, enzymologic properties, gross structure, and tissue distribution. J. Invest. Dermatol. 101 (1993) 346-351
146. Suzaki Y., Yoshizumi M., Yamashita Y., Abe S., Tsuchiya K., Satoh Y., Kuroda Y., Horike K., Kano M., Fukata Y., Kitaichi T., Hori T., Masuda Y., Kitagawa T., Minakuchi K., and Tamaki T. Determination of plasma concentrations of endothelin-1(1-31) and endothelin-1 in healthy subjects and patients with atherosclerosis. J. Cardiovasc. Pharmacol. 41 Suppl 1 (2003) S83-S87
147. Takahashi M., Fukuda K., Shimada K., Barnes K., Turner A.J., Ikeda M., Koike H., Yamamoto Y., and Tanzawa K. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem. J. 311 Pt 2 (1995) 657-665
148. Takai S., Shiota N., Jin D., and Miyazaki M. Chymase processes big-endothelin-2 to endothelin-2-(1-31) that induces contractile responses in the isolated monkey trachea. Eur. J. Pharmacol. 358 (1998) 229-233
149. Takai S., Yuda A., Jin D., Nishimoto M., Sakagichi M., Sasaki S., and Miyazaki M. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 467 (2000) 141-144
150. Takai S., Jin D., Sakaguchi M., Kirimura K., and Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn. J. Pharmacol. 86 (2001) 124-126
151. Takai S., Jin D., Nishimoto M., Yuda A., Sakaguchi M., Kamoshita K., Ishida K., Sukenaga Y., Sasaki S., and Miyazaki M. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci. 69 (2001) 1725-1732
152. Takai S., Jin D., Sakaguchi M., Katayama S., Muramatsu M., Matsumura E., Kim S., and Miyazaki M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo -a zetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 305 (2003) 17-23
153. Takao K., Takai S., Ishihara T., Mita S., and Miyazaki M. Inhibition of human chymase by suramin. Jpn. J. Pharmacol. 81 (1999) 404-407
154. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., Inoue N., Hirata K., and Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
155. Tani M., Gyobu Y., Sasaki T., Takenouchi O., Kawamura T., Kamimura T., and Harada T. SF2809 compounds, novel chymase inhibitors from Dactylosporangium sp. 1. Taxonomy, fermentation, isolation and biological properties. J. Antibiot. (Tokyo) 57 (2004) 83-88
156. Tchougounova E., Forsberg E., Angelborg G., Kjellen L., and Pejler G. Altered processing of fibronectin in mice lacking heparin. a role for heparin-dependent mast cell chymase in fibronectin degradation. J. Biol. Chem. 276 (2001) 3772-3777
157. Tchougounova E., and Pejler G. Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase. Faseb J. 15 (2001) 2763-2765
158. Tchougounova E., Pejler G., and Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J. Exp. Med. 198 (2003) 423-431
159. Tchougounova E., Lundequist A., Fajardo I., Winberg J.O., Abrink M., and Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J. Biol. Chem. 280 (2005) 9291-9296
160. Till J.E., Siminovitch L., and McCulloch E.A. The effect of plethora on growth and differentiation of normal hemopoietic colony-forming cells transplanted in mice of genotype W/Wv. Blood 29 (1967) 102-113
161. Tirapelli C.R., Fecteau M.H., Honore J.C., Legros E., Gobeil F., and D'Orleans-Juste P. Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta. Br. J. Pharmacol. 148 (2006) 527-535
162. Tomimori Y., Muto T., Fukami H., Saito K., Horikawa C., Tsuruoka N., Yamashiro K., Saito M., Sugiura N., Sumida M., Kakutani S., and Fukuda Y. Mast cell chymase regulates dermal mast cell number in mice. Biochem. Biophys. Res. Commun. 290 (2002) 1478-1482
163. Turner A.J., and Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Faseb J. 11 (1997) 355-364
164. Turner A.J., Barnes K., Schweizer A., and Valdenaire O. Isoforms of endothelin-converting enzyme: why and where?. Trends Pharmacol. Sci. 19 (1998) 483-486
165. Umezawa H., Aoyagi T., Morishima H., Kunimoto S., and Matsuzaki M. Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes. J. Antibiot. (Tokyo) 23 (1970) 425-427
166. Waeber B. Vasopeptidase inhibition: a new approach to the management of cardiovascular disease. J. Clin. Hypertens. (Greenwich) 2 (2000) 87-93
167. Warner T.D., de Nucci G., and Vane J.R. Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur. J. Pharmacol. 159 (1989) 325-326
168. Wastling J.M., Knight P., Ure J., Wright S., Thornton E.M., Scudamore C.L., Mason J., Smith A., and Miller H.R. Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am. J. Pathol. 153 (1998) 491-504
169. Watts S.W., Thakali K., Smark C., Rondelli C., and Fink G.D. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol. 47 (2007) 302-312
170. Wu Q., Kuo H.C., and Deng G.G. Serine proteases and cardiac function. Biochim. Biophys. Acta. 1751 (2005) 82-94
171. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., and Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78 (1994) 473-485
172. Yanagihara Y., Kasai H., and Shida T. Immunopharmacological studies on TBX, a new antiallergic drug (2). Inhibitory effects on histamine release from peritoneal mast cells and lung fragments of rats. Jpn J Pharmacol. 48 (1988) 103-112
173. Yanagihara Y., Kasai H., Matsui S., and Ninomiya K. Immunopharmacological studies on TBX, a new antiallergic drug (3). Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. Jpn. J. Pharmacol. 51 (1989) 83-92
174. Yanagisawa H., Yanagisawa M., Kapur R.P., Richardson J.A., Williams S.C., Clouthier D.E., de Wit D., Emoto N., and Hammer R.E. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125 (1998) 825-836
175. Yanagisawa H., Hammer R.E., Richardson J.A., Emoto N., Williams S.C., Takeda S., Clouthier D.E., and Yanagisawa M. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 105 (2000) 1373-1382
176. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
177. Yasuoka H., Yoshizumi M., Inui D., Okishima N., Houchi H., Kirima K., Oshita S., Kido H., and Tamaki T. Effect of endothelin-1(1-31) on intracellular free calcium in cultured human mesangial cells. Life Sci. 65 (1999) PL267-PL272
178. Yoshizumi M., Kim S., Kagami S., Hamaguchi A., Tsuchiya K., Houchi H., Iwao H., Kido H., and Tamaki T. Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br. J. Pharmacol. 125 (1998) 1019-1027
179. Yoshizumi M., Inui D., Okishima N., Houchi H., Tsuchiya K., Wakabayashi H., Kido H., and Tamaki T. Endothelin-1-(1-31), a novel vasoactive peptide, increases [Ca2+]i in human coronary artery smooth muscle cells. Eur. J. Pharmacol. 348 (1998) 305-309
180. Yoshizumi M., Inui D., Kirima K., Tsuchiya K., Houchi H., Azuma M., Yasuoka H., Kido H., and Tamaki T. Comparison of the effects of endothelin-1, -2 and -3 (1-31) on changes in [Ca2+]i in human coronary artery smooth muscle cells. Jpn. J. Pharmacol. 81 (1999) 298-304
181. Yoshizumi M., Kagami S., Suzaki Y., Tsuchiya K., Houchi H., Hisayama T., Fukui H., and Tamaki T. Effect of endothelin-1 (1-31) on human mesangial cell proliferation. Jpn. J. Pharmacol. 84 (2000) 146-155
182. Yurt R., and Austen K.F. Preparative purification of the rat mast cell chymase: characterization and interaction with granule components. J. Exp. Med. 146 (1977) 1405-1419
183. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., and Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1706-1721
184. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471